Project Grant R21CA309329
- Federal Project Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025 through August 31, 2027. This award supports the development of an integrative framework for surface protein imputation in spatial biology applications. The project delivers machine learning (ML) methodologies and computational tools designed to predict surface protein abundance...
- Federal Project Grant Award Summary The University of Pittsburgh received a $261,662 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with completion targeted for April 16, 2029. This award supports an integrated in silico and in vivo genetic screening research initiative designed to identify subtype-specific hepatocellular carcinoma (HCC) genetic dependencies. The project addresses a significant clinical...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on December 12, 2025, with a completion date of November 30, 2027. This award supports biomedical research training and career development in cancer research aligned with the National Cancer Program's strategic priorities. The grant funds research investigating the relative and synergistic contributions of...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh $109,076 under the Cancer Research Manpower program (CFDA 93.398) on January 21, 2026, with a completion date of July 31, 2029. This project grant funds research to develop innovative computational and analytical tools for tracking metastatic breast cancer subclones and predicting therapeutic vulnerabilities. The research integrates machine learning techniques, including transformer...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $141,566 Project Grant on March 24, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training and career development in cancer research. The grant funds research focused on understanding the conformational landscape and regulation of small GTPases (SMGs), specifically examining how oncogenic RhoA proteins function in cancer cell environments. The project...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a Project Grant of $658,492 under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC). The research, spanning from March 18, 2026 through February 28, 2031, focuses on optimizing the combination of CHK1 inhibitor SRA737 and WEE1 inhibitor AZD1775 to exploit the G2/M...
- Federal Grant Award Summary The University of Pittsburgh received a $149,804 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded March 1, 2025, with completion scheduled for February 28, 2026. This award supports research investigating the impact of LAG3 (Lymphocyte Activation Gene 3) on CD8+ T cell motility and migration in the context of cancer immunotherapy. The research builds upon preliminary findings demonstrating that...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $151,920 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This award supports fundamental research to develop and validate Nuclear Magnetic Resonance (NMR) strategies for investigating allosteric inhibitor binding effects on Src-family kinases implicated in acute myeloid leukemia (AML). The research aims to characterize...
- Federal Grant Award Summary The University of Pittsburgh has received a $121,857 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective August 1, 2025, through July 31, 2027. This award supports a K99/R00 Pathway to Independence research project investigating how anti-cancer drugs modulate T cell activity within the tumor microenvironment to overcome immune checkpoint blockade (ICB) resistance. The research delivers three integrated...
- Federal Project Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded March 13, 2026, with completion targeted for February 29, 2028. This award funds research investigating immunosuppression mediated by regulatory CD8+ T cells in lung cancers, with the objective of improving immunotherapy efficacy for non-small cell lung cancer (NSCLC) and small cell lung cancer...
The University of Pittsburgh received a $412,856 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2028. This award funds research investigating the role of cell cycle plasticity in bladder cancer growth and progression. The research will generate a systematic catalog of cell cycle heterogeneity across 661 bladder tumors using single-cell spatial proteomics and machine learning methodologies, with deliverables including the first comprehensive characterization of distinct cell cycle programs in bladder cancer and a publicly available single-cell proteomic dataset mapping cell cycle effectors and tumor microenvironment (TME) biomarkers. Through three integrated research aims, the project will catalog cell cycle programs across diverse bladder cancer histological and molecular subtypes, investigate how specific TME configurations influence cell cycle regulation using graph neural networks, and develop experimental models that recapitulate identified cell cycle programs for mechanistic studies. The research outcomes are intended to advance fundamental understanding of bladder cancer biology and establish a foundation for future biomarker discovery and therapeutic targeting strategies to improve patient outcomes through precision oncology approaches.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $412.9k | 4/17/26 |